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Summary Our previous experimental studies have shown that the best approach to increase the biological
anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association
with immunomodulating neurohormones, in an attempt to reproduce the physiological links between
psychoendocrine and immune systems, which play a fundamental role in the regulation of the immune
responses. In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to
cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone. To confirm these
preliminary results, a clinical trial was performed in locally advanced or metastatic patients with solid tumours
other than renal cell cancer and melanoma. The study included 80 consecutive patients, who were randomised
to be treated with IL-2 alone subcutaneously (3 million IU day-' at 8.00 p.m. 6 days a week for 4 weeks) or
IL-2 plus MLT (40 mg day-' orally at 8.00 p.m. every day starting 7 days before IL-2). A complete response
was obtained in 3/41 patients treated with IL-2 plus MLT and in none of the patients receiving IL-2 alone. A
partial response was achieved in 8/41 patients treated with IL-2 plus MLT and in only 1/39 patients treated
with IL-2 alone. Tumour objective regression rate was significantly higher in patients treated with IL-2 and
MLT than in those receiving IL-2 alone (11/41 vs 1/39, P<0.001). The survival at 1 year was significantly
higher in patients treated with IL-2 and MLT than in the IL-2 group (19/41 vs 6/39, P<0.05). Finally, the
mean increase in lymphocyte and eosinophil number was significantly higher in the IL-2 plus MLT group than
in patients treated with IL-2 alone; on the contrary, the mean increase in the specific marker of macrophage
activation neopterin was significantly higher in patients treated with IL-2 alone. The treatment was well
tolerated in both groups of patients. This study shows that the concomitant administration of the pineal
hormone MLT may increase the efficacy of low-dose IL-2 subcutaneous therapy.
Several investigators (Grimm et al., 1982) have demonstrated
that the anti-tumour immune response is essentially an
interleukin 2 (IL-2)-dependent immune phenomenon in
human neoplasms, since most cells involved in cancer cell
destruction (e.g. NK cells, LAK cells and cytotoxic T lym-
phocytes) are under physiological stimulatory control exerted
by IL-2 itself. Despite the essential role of IL-2 in host
anti-tumour immune defences, very few solid tumour histo
types, mainly renal cell cancer and melanoma, appear to
respond to IL-2 immunotherapy (Dillman et al., 1991) in
terms of objective tumour regression. Several cytokines have
been evaluated in association with IL-2 in an attempt to
improve its clinical results, including interferons, tumour
necrosis factor (TNF) and interleukin 6 (IL-6), without, how-
ever, any clear amplification of IL-2 efficacy (Atzpodien &
Kirchner, 1990). The lack of efficacy of IL-2 alone in most
solid tumour histotypes may depend at least in part on the
concomitant generation of suppressive events, mainly
mediated by macrophages (Lissoni et al., 1991). Moreover,
immune responses depend not only on immune factors, but
also on a great number of interactions between cytokines and
neurohormones with immunomodulating effects, in particular
the pineal indole melatonin (MLT) (Maestroni et al., 1986).
On the basis of these considerations, we have investigated
possible improvements in IL-2 anti-tumour efficacy by a
neuroendocrine approach. Our preliminary data have shown
that the concomitant administration of the pineal hormone
MLT may improve the biological effects (Lissoni et al., 1992)
and the anti-tumour activity (Lissoni et al., 1993) of low-dose
IL-2 in cancer histotypes that are generally non-responsive to
IL-2 alone. MLT could amplify IL-2 activity by antagonising
the generation of macrophage-mediated suppressive events
(Lissoni et al., 1993). To confirm these preliminary data, a
randomised study was started with low-dose IL-2 vs IL-2
plus MLT in advanced solid neoplasms other than renal cell
cancer and malignant melanoma.
Patients and methods
From May 1991 to April 1992, 80 consecutive patients with
advanced solid tumour who refused chemotherapy or did not
respond to previous chemotherapies were randomised with-
out stratification to be treated with IL-2 or IL-2 plus MLT.
Eligibility criteria included histologically proven solid
tumour, measurable lesions, inability to tolerate IL-2 at the
conventional high doses or further polychemotherapies
because of age, heavy pretreatments, low performance status
(PS) and/or concomitant medical illnesses. Patients with
brain metastases, double tumours or receiving long-term
steroid therapy were not included in the study. The experi-
mental protocol was explained to each patient, and informed
consent was obtained. Patient characteristics are shown in
Table I. Human recombinant IL-2 was supplied by Euro-
Cetus (Amsterdam, Holland). MLT was supplied by Medea
Research (Milan, Italy). IL-2 was injected subcutaneously
into different parts of the abdominal wall at 3 million
IU day-' at 8.00 p.m. for 6 days a week for four consecutive
weeks, corresponding to one cycle of therapy. MLT was
given orally at a dose of 40 mg day-' at 8.00 p.m. every day,
starting 7 days before the first IL-2 injection as an induction
phase to enhance IL-2 efficacy (Lissoni et al., 1992). We
decided to give IL-2 subcutaneously because of the docu-
mented lower toxicity of this route in comparison with the
intravenous route of administration (Atzpodien et al., 1990;
Stein et al., 1991). Moreover, we decided to administer both
IL-2 and MLT in the evening because of the higher lympho-
cyte sensitivity at this time of the day (Ritchie et al., 1983;
Lissoni et al., 1992). A second immunotherapeutic cycle was
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Table I Main characteristics of cancer patients treated with IL-2 or
IL-2 plus MLT
Characteristic IL-2 IL-2 + MLT
n 39 41
M/F 21/18 22/19
Median age (years) 56 53
(range) (42-71) (36-74)
Performance status 60 60
(Karnofsky's score) (30-80) (20-80)
Tumour histotype
Non-small cell lung cancer 9 12
Colorectal cancer 11 8
Hepatocarcinoma 5 7
Gastric cancer 5 6
Pancreas adenocarcinoma 5 5
Breast cancer 4 3
Sites of disease
No metastasis 4 3
Distant metastases 35 38
Soft tissue 1 0
Bone 5 6
Lung 12 13
Liver 9 10
Liver and lung 6 7
Serosa 2 2
Previous chemotherapy 18/39 22/41
given after a rest period of 3 weeks, after which patients
underwent a maintenance therapy for 1 week every month
until disease progression or toxicity.
Radiological examinations were made before the
immunotherapy, after each cycle of treatment and then every
2 months. Liver metastases were investigated by CT scan.
Clinical response and toxicity were evaluated according to
WHO criteria. Complete response (CR) was defined as a
complete resolution of all clinically evaluable disease for at
least 1 month; partial response (PR) was defined as at least
50% reduction in the sum of the products of the longest
perpendicular diameters of measurable lesions for at least 1
month; stable disease (SD) was defined as no objective
tumour regression or increase greater than 25%; progressive
disease (PD) was defined as at least 25% increase in
measurable lesions or the appearance of new lesions. Patients
were considered as evaluable when they received at least one
complete immunotherapeutic cycle. Patients were observed
for a minimum follow-up of 13 months, and the median
follow-up was 18 months.
Routine laboratory tests, including leucocyte count and
electrocardiogram, were performed before and at weekly
intervals during the immunotherapeutic cycles, then every 15
days. Moreover, to investigate macrophage activation, serum
levels of the specific macrophage marker neopterin were also
measured at weekly intervals by the radioimmunoassay
(RIA) method with commercially available kits (Henning,
Berlin, Germany). Changes in immune parameters during the
study were evaluated on the basis of multiple measurements
for individual patients.
Data were statistically analysed by the chi-square test, the
Student's t-test and analysis of variance according to the
Newman-Keuls test adjusted for a correction factor, as ap-
propriate.
Results
The clinical response to therapy in both groups of patients is
reported in Table II. Among patients treated with IL-2 plus
MLT, CR was achieved in 3/41 (7%). The first CR was seen
in a patient with liver metastases from gastric adenocar-
cinoma, and abdominal node recurrence and who is still alive
after a follow-up of 21 months. The second CR was obtained
in a patient with locally advanced adenocarcinoma of pan-
creas who underwent palliative surgery, while the third CR
was achieved in a patient with hepatocarcinoma and liver
cirrhosis. These patients are still free from disease after 11
and 7 months respectively.
Within the group treated with IL-2 alone, no patient
obtained a CR. PR was obtained in 8/41 (19%) patients
treated with IL-2 plus MLT (lung cancer, 3; hepatocar-
cinoma, 2; gastric adenocarcinoma, 1; colon adenocarcinoma,
1; breast cancer, 1), with a median duration of response of
9 + months (range 2-25 +). Therefore, the objective tumour
regression rate seen in patients treated with IL-2 plus MLT
was 11/41 (26%). Stable disease was observed in 12/41 (30%)
patients receiving IL-2 plus MLT, whereas the remaining
18/41 (44%) patients progressed. In the group treated with
IL-2 alone, a PR was achieved only in 1/39 (3%) patients,
who was affected by locally advanced hepatocarcinoma
(duration: 5 months). Eleven other patients (28%) had SD,
while the other 27 (69%) progressed. Tumour response rate
was significantly higher in patients treated with IL-2 plus
MLT than in those receiving IL-2 alone (11/41 vs 1/39,
P<0.005). Moreover, the progression-free survival
(mean ± s.e.) was significantly higher in patients treated with
IL-2 plus MLT than in those treated with IL-2 alone (9 ± 1
vs 4+ 1 months, P<0.05). Finally, according to log-rank
test, percentage survival at 1 year was significantly higher in
the IL-2 plus MLT group than in patients treated with IL-2
alone (19/41 vs 6/39, P<0.05). The percentage survival at 1
year observed in the two groups of patients is illustrated in
Figure 1.
Toxicity was low in both groups of patients, and in parti-
cular no cardiovascular complication occurred. Some side-
effects were apparently less frequent in patients treated with
IL-2 plus MLT than in those treated with IL-2 alone, with-
out, however, any significant difference. The main toxicities
observed in the two groups of patients are reported in Table
III. As far as the biological data are concerned, no significant
difference was seen between patients treated with IL-2 alone
or IL-2 plus MLT in the pretreatment values of lymphocytes
(1346 ± 186 vs 1274 ± 241 mm-3) and eosinophils (97 ± 13 vs
104 25 mm-3) and serum levels of neopterin (3.9 ± 0.7 vs
3.6 0.5 ng ml-1). The mean increase, as documented by at
least six serial measurements in each patient, in the absolute
number of lymphocytes and eosinophils was significantly
higher in patients receiving IL-2 plus MLT than in those
treated with IL-2 alone (lymphocytes, P<0.05; eosinophils,
Table II Clinical results in patients with advanced solid tumours treated with IL-2 or IL-2 plus MLT
Clinical responsea
IL-2 IL-2 + MLT
Tumour histotype n CR PR CR + PR SD PD n CR PR CR + PR SD PD
Overall tumours 39 0 1 1 (3%) 11 27 41 3 8 11 (26%)* 12 18
Non-small cell lung cancer 9 0 0 0 3 6 12 0 3 3 4 5
Colorectal adenocarcinoma 11 0 0 0 1 10 8 0 1 1 2 5
Hepatocarcinoma 5 0 1 1 2 2 7 1 2 3 2 2
Gastric adenocarcinoma 5 0 0 0 2 3 6 1 1 2 2 2
Pancreas adenocarcinoma 5 0 0 0 2 3 5 1 0 1 1 3
Breast cancer 4 0 0 0 1 3 3 0 1 1 1 1
'CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. *P<0.001 vs IL-2 alone.198 P. LISSONI et al.
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Figure 1 Percentage survival at 1 year in patients treated with
IL-2 (0) or with IL-2 plus MLT (a). P<0.05 vs IL-2
alone.
Table III Main toxicities observed in patients treated with IL-2
alone (n = 39) or with IL-2 plus MLT (n = 41)
Toxicity IL-2 IL-2 + MLT
Fever 38°C 6 (15%) 4 (9%)
Nausea and vomiting 2 (5%) 1 (2%)
Anorexia 4 (10%) 2 (5%)
Asthenia 3 (8%) 1 (2%)
Arthralgia/myalgia 1 (2%) 0 (0%)
Diarrhoea 0 (0%) 0 (0%)
Rash 0 (0%) 0 (0%)
Pruritus 0 (0%) 0 (0%)
Depressive symptoms 3 (8%) 1 (2%)
Cardiovascular toxicity 0 (0%) 0 (0%)
Nephrotoxicity 0 (0%) 0 (0%)
Transaminase increase 7 (18%) 4 (9%)
Anaemia 2 (5%) 1 (2%)
Thrombocytopenia 3 (8%) 0 (0%)
P<0.001). However, the mean increase in serum levels of
neopterin observed in the study was significantly higher in
patients treated with IL-2 alone than in those treated with
IL-2 plus MLT (P<0.05). Mean increases in lymphocyte
and eosinophil number and in neopterin levels observed dur-
ing immunotherapy in both groups of patients are illustrated
in Figure 2.
Discussion
In agreement with the results reported by other authors
(Stein et al., 1991), the present study confirms that low-dose
subcutaneous IL-2 is a well-tolerated therapy, capable of
causing important immunobiological effects, such as the pro-
liferation of lymphocytes and eosinophils. However, as
previously shown by other authors (Stein et al., 1991), IL-2
alone is generally unable to induce tumour regressions in
solid neoplasms other than renal cell cancer and melanoma.
This study demonstrates that a neuroimmunotherapeutic
strategy with the pineal hormone MLT may amplify the
anti-tumour activity of low-dose IL-2 and determine objec-
tive tumour regressions potentially in all solid neoplasms,
perhaps by replacing pharmacologically the physiological
links between the neuroendocrine and immune systems,
which are often altered in human cancer. Therefore, this
study seems to suggest that the pineal hormone MLT is
essential for the efficacy of low-dose IL-2 in the treatment of
Lymphocytes Eosinophils Neopterin
Figure 2 Increase (mean ± s.e.) in the absolute number of lym-
phocytes and eosinophils and in the serum levels of neopterin
(mean ± s.e.) in cancer patients treated with IL-2 (0) or IL-2
plus MLT (0). P<0.05, **P<0.001 vs IL-2; ***P<0.05 vs IL-
2 + MLT.
advanced solid neoplasms that are generally resistent to IL-2
alone. The mechanisms by which MLT may potentiate the
anti-cancer activity of IL-2 have still to be better defined.
Several experiments have demonstrated that the neuroendo-
crine system plays an important role in influencing the
immune responses, including the anti-cancer reaction. Since
IL-2 has been proven to modulate the neuroendocrine system
(Denicoff et al., 1989) and to affect the activity of the pineal
gland (Lissoni et al., 1990), which represents one of the most
important organs involved in the neuroimmunomodulation
and in the control of cancer growth (Maestroni et al., 1986),
it could be important to correct the possible alterations in the
neuroimmune relationship induced by the exogenous injec-
tion of cytokines through an exogenous administration of
immunomodulating neurohormones, such as the pineal
indole MLT. The present study shows that the concomitant
administration of MLT is associated with a greater increase
in the number of cells involved in the anti-tumour response
during IL-2 immunotherapy, including lymphocytes and
eosinophils (West, 1989). On the contrary, the administration
of MLT would seem to induce a lower activation of mac-
rophages, as evaluated by the determining neopterin levels, in
response to IL-2. Since macrophages have been proven to
inhibit the action of anti-tumour cytotoxic lymphocytes
(Broder et al., 1978), the neutralisation of macrophage-
mediated immunosuppressive events could constitute one of
the most important mechanisms responsible for MLT-
induced amplification of IL-2 anti-tumour efficacy. However,
since MLT may have an anti-tumour cytostatic action per se
(Maestroni et al., 1986), a direct action of the pineal hor-
mone on cancer growth and/or on the immune system cannot
be excluded. Therefore, the relation between immuno-
biological effects of MLT and clinical response remains
uncertain. In any case, further clinical trials in a greater
number of cases, by randomising patients after stratification
in relation to cancer histotype, sites and extension of the
disease, will be required to confirm and better define the
synergistic action between MLT and IL-2.
In conclusion, this study demonstrates that a neuro-
immunotherapeutic strategy with the pineal immuno-
modulating hormone MLT may enhance the biological
activity of IL-2, increase tumour regression rate and prolong
progression-free survival and overall survival time in patients
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with advanced solid tumours treated with low-dose sub-
cutaneous IL-2 immunotherapy. Therefore, neuroendocrino-
immunology, which originated some years ago as a new
biological philosophy, may constitute a new therapeutic
strategy in cancer, as well as in other human diseases charac-
terised by immune disorders.
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